

# National Board of Examinations

**Question Paper Name :** DrNB Medical Oncology Paper2

**Is this Group for Examiner? :** No

**Enable Mark as Answered Mark for Review and Clear Response :** Yes

## **Question Number : 1 Question Type : SUBJECTIVE**

- a) What is early and delayed emesis in the context of chemotherapy induced vomiting? What will be your algorithm for preventing emesis in a patient receiving highly emetogenic chemotherapy in an adult? [4]
- b) Non pharmacological methods of pain management. [3]
- c) Early integration of palliative care in cancer. [3]

## **Question Number : 2 Question Type : SUBJECTIVE**

- a) Risk stratification and role of NGS in AML. [3]
- b) Targeted agents in AML. [3]
- c) Therapy related AML and its management. [4]

## **Question Number : 3 Question Type : SUBJECTIVE**

- a) Methods of fertility preservation in adolescents and young adult women. [3]
- b) Metabolic syndrome in the context of cancer survivorship: risk factors and detection. [4]
- c) How will you manage hand foot syndrome? [3]

## **Question Number : 4 Question Type : SUBJECTIVE**

- a) What are high risk pathological and molecular markers in Wilms tumor? [4]
- b) Morphological and immunohistochemical characteristics of nodular lymphocyte predominant

Hodgkin's lymphoma. [3]

c) Pathological characteristics of ductal carcinoma in situ. [3]

**Question Number : 5 Question Type : SUBJECTIVE**

a) What are adaptive clinical trials? Explain with example. [4]

b) Write briefly on Forrest plot. [3]

c) What is bioinformatics? Explain using an example the role of bioinformatics in cancer research. [3]

**Question Number : 6 Question Type : SUBJECTIVE**

a) Define paraneoplastic syndrome. [2]

b) Enumerate paraneoplastic syndromes in the context of lung cancer. [5]

c) Diagnosis and management of SIADH. [3]

**Question Number : 7 Question Type : SUBJECTIVE**

a) Etiology of cancer related fatigue. [3]

b) Components of comprehensive fatigue evaluation. [3]

c) Assessment of frailty in elderly patients for cancer chemotherapy. [4]

**Question Number : 8 Question Type : SUBJECTIVE**

a) PSMA-PET scan. [3]

b) Adverse effects of local treatment in carcinoma prostate. [3]

c) Newer advances in treatment of castration resistant metastatic prostate cancer. [4]

**Question Number : 9 Question Type : SUBJECTIVE**

a) Define febrile neutropenia. [3]

b) Prevention and treatment of febrile neutropenia. [4]

c) Role of anti-fungals in oncology. [3]

**Question Number : 10 Question Type : SUBJECTIVE**

a) Principles of immune check point inhibitors. [3]

b) Response evaluation criteria for immunotherapy. [3]

c) Management of adverse events of immunotherapy. [4]